A senator opposes the Biden drug price negotiation plan and proposes a new model to help manage weight loss drug costs; Black children are underdiagnosed with attention-deficit/hyperactivity disorder (ADHD) compared with their White peers; lawmakers and witnesses said that policy makers must balance innovation with potential harms when it comes to artificial intelligence (AI) in health care.
Amid the recent FDA approval of tirzepatide for weight management, Sen Bill Cassidy (R, Louisiana) proposed that federal agencies take the lead on researching ways to transition people off weight loss medicines to keep costs down, according to STAT. Cassidy, the highest-ranking Republican on the Senate’s health policy committee, opposed President Joe Biden’s plan to manage weight loss drug costs, which would let the government negotiate directly with pharmaceutical companies, arguing that it reduces incentives to develop new therapies and may not reduce patients’ costs. Cassidy and economists warned that it is not cost-effective for commercial insurers and federal health programs to pay for lifelong use of weight loss therapies, resulting in the proposal of his model. He explained that an economist suggested that the National Institutes of Health craft sponsored studies where a patient has a year’s worth of treatment and then has it substituted with dietary therapy, like meal deliveries, to reduce costs.
Black children are underdiagnosed and undertreated for attention-deficit/hyperactivity disorder (ADHD) compared with their White peers, according to KFF Health News. A Penn State report that followed more than 10,000 elementary students nationwide from kindergarten to fifth grade found that Black students received an ADHD diagnosis 40% less than White students; the researchers found young Black boys to be diagnosed 60% less than their White counterparts. This racial divide is deepening inequity for Black children, especially Black males. For example, studies have shown that ADHD underdiagnosis contributes to harsher school discipline and the “school-to-prison” pipeline as Black youth routinely face punishment for problem behavior and mental health conditions while White youth are more likely to receive medical diagnoses and treatment. To fix these inequities, mental health experts suggested increasing culturally sensitive screening and addressing Black families’ concerns about potential bias and racism.
Lawmakers and witnesses said during a Senate hearing on Wednesday that policy makers must balance innovation with potential harms to health care workers and patients when it comes to artificial intelligence (AI) in health care, according to MedPage Today. At the Subcommittee on Primary Health and Retirement Security hearing, Chair Edward Markey (D, Massachusetts) began by discussing the potential dangers of unregulated experimentation of AI in health care, warning that failing to produce effective AI in health care policies could jeopardize patient privacy or lead to misdiagnoses or mistreatment of patients. Several witnesses invited to testify agreed with Markey’s concerns, while some focused more on AI’s potential benefits. The subcommittee members explained their goal of balancing the protection of patients with allowing innovation to flourish, emphasizing the need for effective, thoughtful AI in health care policies.
Varied Access: The Pharmacogenetic Testing Coverage Divide
February 18th 2025On this episode of Managed Care Cast, we speak with the author of a study published in the February 2025 issue of The American Journal of Managed Care® to uncover significant differences in coverage decisions for pharmacogenetic tests across major US health insurers.
Listen
Reducing Readmissions in the Safety Net Through AI and Automation
March 6th 2025Artificial intelligence (AI) and electronic health record–based automation tools helped a safety-net health system meet performance-based readmission metrics, thereby retaining critical funding while improving clinical and equity outcomes.
Read More
Senate Questions NIH Nominee on Funding, Transparency, and COVID-19 Impact
March 5th 2025Jay Bhattacharya, MD, PhD, defended his vision for the National Institutes of Health in a Senate committee confirmation hearing, tackling concerns on research funding, public trust, and scientific integrity.
Read More